Display options
Cite
Dyck PJB, Tracy JA. History, Diagnosis, and Management of Chronic Inflammatory Demyelinating Polyradiculoneuropathy. Mayo Clin Proc. 2018;93(6):777-793doi: 10.1016/j.mayocp.2018.03.026.
Dyck, P. J. B., & Tracy, J. A. (2018). History, Diagnosis, and Management of Chronic Inflammatory Demyelinating Polyradiculoneuropathy. Mayo Clinic proceedings, 93(6), 777-793. https://doi.org/10.1016/j.mayocp.2018.03.026
Dyck, P James B, and Tracy, Jennifer A. "History, Diagnosis, and Management of Chronic Inflammatory Demyelinating Polyradiculoneuropathy." Mayo Clinic proceedings vol. 93,6 (2018): 777-793. doi: https://doi.org/10.1016/j.mayocp.2018.03.026
Dyck PJB, Tracy JA. History, Diagnosis, and Management of Chronic Inflammatory Demyelinating Polyradiculoneuropathy. Mayo Clin Proc. 2018 Jun;93(6):777-793. doi: 10.1016/j.mayocp.2018.03.026. PMID: 29866282.
Copy Download .nbib Format: NLM
Share it on

Mayo Clin Proc. 2018 Jun;93(6):777-793. doi: 10.1016/j.mayocp.2018.03.026.

History, Diagnosis, and Management of Chronic Inflammatory Demyelinating Polyradiculoneuropathy.

Mayo Clinic proceedings

P James B Dyck, Jennifer A Tracy

Affiliations

  1. Department of Neurology, Mayo Clinic, Rochester, MN. Electronic address: [email protected].
  2. Department of Neurology, Mayo Clinic, Rochester, MN.

PMID: 29866282 DOI: 10.1016/j.mayocp.2018.03.026

Abstract

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is probably the best recognized progressive immune-mediated peripheral neuropathy. It is characterized by a symmetrical, motor-predominant peripheral neuropathy that produces both distal and proximal weakness. Large-fiber abnormalities (weakness and ataxia) predominate, whereas small-fiber abnormalities (autonomic and pain) are less common. The pathophysiology of CIDP is inflammatory demyelination that manifests as slowed conduction velocities, temporal dispersion, and conduction block on nerve conduction studies and as segmental demyelination, onion-bulb formation, and endoneurial inflammatory infiltrates on nerve biopsies. Although spinal fluid protein levels are generally elevated, this finding is not specific for the diagnosis of ClDP. Other neuropathies can resemble CIDP, and it is important to identify these to ensure correct treatment of these various conditions. Consequently, metastatic bone surveys (for osteosclerotic myeloma), serum electrophoresis with immunofixation (for monoclonal gammopathies), and human immunodeficiency virus testing should be considered for testing in patients with suspected CIDP. Chronic inflammatory demyelinating polyradiculoneuropathy can present as various subtypes, the most common being the classical symmetrical polyradiculoneuropathy and the next most common being a localized asymmetrical form, multifocal CIDP. There are 3 well-established, first-line treatments of CIDP-corticosteroids, plasma exchange, and intravenous immunoglobulin-with most experts using intravenous immunoglobulin as first-line therapy. Newer immune-modulating drugs can be used in refractory cases. Treatment response in CIDP should be judged by objective measures (improvement in the neurological or electrophysiological examination), and treatment needs to be individualized to each patient.

Copyright © 2018 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.

MeSH terms

Publication Types